OpenLegislation

The Misuse of Drugs (Designation) (Amendment No.2) Order (Northern Ireland) 2014

S.R. 2014/159 · Made 5 June 2014

Original text. legislation.gov.uk does not revise statutory instruments, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Dangerous Drugs

Made 5th June 2014

Coming into operation 26th June 2014

The Department of Health, Social Services and Public Safety makes the following Order in exercise of the powers conferred by section 7(4) of the Misuse of Drugs Act 1971 f1 as adapted by section 7(9) of that Act and now vested in it f2 and after consultation with the Advisory Council on the Misuse of Drugs in accordance with section 7(7) of that Act.

Annotations to the whole text

Footnotes

f1

1971 c.38 as amended by s.151 of and Schedule 17 to the Police Reform and Social Responsibility Act 2011 c.13.

f2

S.R. & O. (N.I.) 1973 No.504; Article 5(a) and S.I.1999/283 (N.I.1), Article 3(6)

Contents

  1. 1Citation, commencement and interpretation
  2. 2Amendment of the Misuse of Drugs (Designation) Order 2001
  3. Signature
  4. Explanatory note

1Citation, commencement and interpretation

(1)

This Order may be cited as the Misuse of Drugs (Designation) (Amendment No.2) Order (Northern Ireland) 2014 and shall come into operation on 26th June 2014.

(2)

The Interpretation Act (Northern Ireland) 1954 f1 shall apply to this Order as it applies to an Act of the Northern Ireland Assembly.

2Amendment of the Misuse of Drugs (Designation) Order 2001

In Part 1 of the Schedule to the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 f1 (controlled drugs to which section 7(4) of the Misuse of Drugs Act applies), after paragraph 1(t) insert—

“(u)

Any compound (not being benzyl(α-methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy-α-methylphenethylamine, 2,5-dimethoxy-α,4-dimethylphenethylamine, N-hydroxytenamphetamine, or a compound specified in sub-paragraph (c) or (d) above by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent.

(v)

Any compound (not being a compound for the time being specified in sub-paragraph (c) above) structurally derived from 1-benzofuran, 2,3-dihydro-1-benzofuran, 1H-indole, indoline, 1H-indene, or indane by substitution in the 6-membered ring with a 2-ethylamino substituent whether or not further substituted in the ring system to any extent with alkyl, alkoxy, halide or haloalkyl substituents and whether or not substituted in the ethylamino side-chain with one or more alkyl substituents.”

Signature

Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 5th June 2014

L.S.

Dr Liz Reaney

A senior officer of the

Department of Health, Social Services and Public Safety

Explanatory note

(This note is not part of the Order)

Section 7(3) of the Misuse of Drugs Act 1971 requires Regulations to be made to allow the use for medical purposes of the drugs which are subject to control under that Act. Section 7(3) does not apply to any drug designated by order under section 7(4) as a drug to which section 7(4) is to apply. This Order amends the Misuse of Drugs (Designation) Order (Northern Ireland) 2001 by inserting groups of “NBOMe” compounds and groups of benzofuran compounds into Part 1 of the Schedule to that Order.